Clinical Trial Update: A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating antisense PKC-α inhibitor LY900003 (ISIS 3521) with gemcitabine and carboplatin in previously untreated advanced non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• ISIS 3521 (LY900003)
• Paraplatin (Carboplatin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms | Phase 2 | Status: COMPLETED